Olmesartán/Amlodipino Cinfa (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxomil and Amlodipine, the active ingredient in Olmesartán/Amlodipino Cinfa, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension, often in adults who require more than one medication to reach blood pressure goals. GNH USA supplies Olmesartán/Amlodipino Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán/Amlodipino Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine is used in the management of high blood pressure, acting on the renin‑angiotensin system and vascular smooth‑muscle tone. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Hypertension with concomitant cardiovascular risk: provides additional blood‑pressure reduction and may improve overall cardiovascular risk profile. - Resistant hypertension: used as part of a multi‑drug regimen to attain adequate control. - Hypertension in elderly patients: offers once‑daily dosing convenience and tolerability. - Hypertension in patients with metabolic syndrome: assists in blood‑pressure control without adverse metabolic effects.

Olmesartan/Amlodipine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Peripheral edema: mild swelling, usually of the ankles. - Headache: transient, often resolves with continued therapy. - Dizziness: related to blood‑pressure lowering. - Flushing: brief sensation of warmth. - Fatigue: general tiredness. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Angio‑edema: swelling of face, lips, tongue, or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: abnormal liver enzymes. - Myocardial infarction: rare but reported in susceptible patients. - Renal impairment: worsening kidney function. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Olmesartan/Amlodipine, clinicians should consider several safety aspects. - Renal function: assess baseline kidney function and monitor periodically. - Hepatic function: evaluate liver enzymes before initiation. - Electrolyte balance: watch for potassium abnormalities, especially with concomitant diuretics. - Pregnancy: avoid use; drug is contraindicated in pregnancy. - Elderly patients: start at lower dose and monitor for hypotension. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase amlodipine levels. - NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive blood‑pressure lowering.\n- Lithium: increased risk of lithium toxicity. - Rifampicin: may reduce olmesartan exposure. - Diuretics: may enhance hypotensive effect. - Alcohol: can potentiate dizziness and hypotension.